Listed by the USPTO as POPA, ILEANA
Tech Center 1600 • Art Units: 1600 1633 1663
This examiner grants 22% of resolved cases
Ileana Popa has 849 resolved cases in Tech Center 1600 and Art Unit 1600. The profile records a 21.7% allowance rate and a median of 1716 days to allowance. Interviews are associated with a 15.7% lift in the allowance rate. The allowance and pendency figures indicate that applicants should plan for extended prosecution and carefully manage claim amendments, evidence, and continuation decisions.
The leading companies are Janssen Pharmaceuticals Inc., The United States Department of Health and Human Services, and Translate Bio Inc. The leading firms are SUGHRUE MION, PLLC, Lathrop GPM LLP | Sanofi-Aventis, and Adams & Reese LH. The profile provides relevant context for pharmaceutical and biotechnology applications.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18711131 | Method of Treating Geographic Atrophy with a Gene Therapy Vector Expressing Soluble CD59 | Non-Final OA | Janssen Biotech, Inc. |
| 18583364 | Neoantigens Expressed In Ovarian Cancer And Their Uses | Non-Final OA | Janssen Biotech, Inc. |
| 17054393 | METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS | Final Rejection | Beam Therapeutics Inc. |
| 18088544 | POLYMERIC NANOPARTICLES AND DERIVATIVES THEREOF FOR NUCLEIC ACID BINDING AND DELIVERY | Final Rejection | University of Massachusetts |
| 19392021 | COMPOSITIONS AND METHODS FOR TREATING GENETIC DISORDERS | Final Rejection | Fundación para la Investigación Biomédica del Hospital Infantil Universitario Niño Jesús |
| 17925470 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | Final Rejection | Ohio State Innovation Foundation |
| 18561253 | PRODUCTION PROCESSES FOR HIGHLY VIABLE, ENGRAFTABLE HUMAN CHONDROCYTES FROM STEM CELLS | Non-Final OA | University of Southern California |
| 18068922 | MAMMALIAN CELL CULTURE | Non-Final OA | AMGEN INC. |
| 17925404 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | Final Rejection | Generation Bio Co. |
| 18022415 | METHOD FOR IN VITRO PRODUCTION OF RED BLOOD CELLS | Final Rejection | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18555385 | SIGNAL PEPTIDES | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 15327794 | SUBSET-OPTIMIZED CHIMERIC ANTIGEN RECEPTOR-CONTAINING T-CELLS | Final Rejection | The Trustees of the University of Pennsylvania |
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | Final Rejection | Universitat Autònoma de Barcelona |
| 18249037 | GLYCOSYLTRANSFERASE VARIANTS FOR IMPROVED PROTEIN PRODUCTION | Final Rejection | Novozymes A/S |
| 19010148 | MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS | Non-Final OA | CRISPR Therapeutics AG |
| 18976790 | VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER | Non-Final OA | The United States of America, as represented by the Secretary, Department of Health and Human Servi |
| 18465333 | COMPOSITONS AND METHODS FOR USE OF KALIUM CHANNEL RHODOPSINS | Non-Final OA | BAYLOR COLLEGE OF MEDICINE |
| 18958046 | Compositions and Methods for Cancer Immunotherapy | Non-Final OA | The UAB Research Foundation |
| 18003646 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 18013789 | MEDIUM COMPOSITION FOR PREPARATION OF INTESTINAL ORGANOID | Non-Final OA | ORGANOIDSCIENCES LTD. |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | Non-Final OA | TRANSLATE BIO, INC. |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Non-Final OA | Translate Bio, Inc. |
| 18853473 | ADENO-ASSOCIATED VIRUS POTENCY ASSAY AND USES THEREOF | Non-Final OA | ASTELLAS GENE THERAPIES, INC. |
| 17496530 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Final Rejection | Acuitas Therapeutics, Inc. |
| 18816718 | T CELLS FOR EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND OTHER RECEPTORS | Non-Final OA | City of Hope |
| 18093902 | METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18557155 | MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIES | Non-Final OA | REGENXBIO INC. |
| 17799533 | NUCLEIC ACID CONSTRUCT THAT CAN MEASURE HOMOLOGOUS RECOMBINATION ACTIVITY, AND METHOD FOR USING SAME | Non-Final OA | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY |
| 18154229 | SUPRAMOLECULAR CELL-BASED CARRIER, DRUG LOADING SYSTEM AND ITS PREPARATION METHOD | Final Rejection | University of Macau |
| 18036472 | GENETICALLY ENGINEERED YEAST CELLS AND METHODS OF USE THEREOF | Final Rejection | Berkeley Fermentation Science Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy21.7% of resolved applications examined by Ileana Popa were allowed (849 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +15.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ileana Popa took 1,716 days on average from filing to allowance.
Ileana Popa examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
